Nkarta to Participate in November Investor Conferences
Rhea-AI Summary
Nkarta (Nasdaq: NKTX) will participate in two investor conferences in November 2025: a Stifel 2025 Healthcare Conference fireside chat on November 12, 2025 at 10:40 a.m. ET and a TD Cowen Immunology & Inflammation Summit fireside chat on November 13, 2025 at 5:00 p.m. ET. A simultaneous webcast will be available on the company’s Investors website at www.nkartatx.com, and a replay will be archived on the site for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, NKTX declined 0.48%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month:
Stifel 2025 Healthcare Conference
November 12, 2025
10:40 a.m. ET – fireside chat
TD Cowen’s Immunology & Inflammation Summit
November 13, 2025
5 p.m. ET – fireside chat
A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Nadir Mahmood
Nkarta, Inc.
nmahmood@nkartatx.com